

Keyholder offer de-risked, asset backed investments directed at disruptive technologies that deliver major advances in the fight against cancer.

Cancer treatment outcomes have significantly improved over the past decade associated with the discovery and advancement of targeted therapies and immunotherapies. Recent progress in the understanding of the biology of cancer now permits rational treatment selection significantly improving survival.

Keyholder Funding Limited is providing selected investment opportunities in the field of Oncology. The opportunities are de-risked, asset-based investment in some of the most exciting, disruptive and potentially profitable developments in the fight against cancer. The developments chosen to be in this investment programme are subjected to an extremely rigorous selection process. They are late stage, transitional assets to be taken to commercialisation.

Keyholder Asset-based Investments

Investment is by purchase of Redeemable Preference Shares (RPSs) in special Purpose UK Companies that hold and control the valuable assets of the projects, being the worldwide patents. The RPS shareholders' investment is supported by the value of these assets which, at any time, far exceed their investment. **RPS investors have first call on the proceeds of sale or realisation of this value at a "Liquidity Event".**

Investment in an unlisted company always carries a higher risk.

- **Longacre Funding Partners LLP selects "transition stage" assets with demonstrable proofs of technical, clinical and market value prior to major value inflection thus providing de-risked and high return opportunities for investors.**
- **The Keyholder Investment Committee recommends funding.**
- **Assets must have enduring value many times the amount of funding committed. Value independently by Valuation Consulting Co**
- **All data and reliance verified by Brabners Solicitors**
- **Special Purpose Company established for investment and control of assets. Independent directors with fiduciary responsibility to preference shareholders.**
- **Target returns 400%-750%**
- **Target term 18 months**


Jan 2020

KEYHOLDER FUNDING

Investment Criteria

- **Unmet need; short time to Liquidity (1-2 yrs);**
- **Major displacing technology;**
- **Valuation based on comparables;**
- **Proof of efficacy in humans;**
- **Long patent protection;**
- **Experienced and competent management.**





Vaccicure PAS (polyclonal antibody stimulator) removes the hormone Gastrin. Safely arrests the growth of many tumours. Cure for 60% of Pancreatic cancers where there is no other cure available. Also found to increase dramatically the effectiveness of checkpoint inhibitors.
Regulatory approval is being sought. Regulatory authorities indicate that Phase 3 approval is expected pending minimal confirmatory trials. Collaboration with big pharma is now taking place for joint trials in combination therapy.

Diatech

ChemoIntel: Diagnostic methods for ranking chemotherapy in order of effectiveness for any individual patient. The ChemoIntel test is based on multiple parameters to eliminate outlier readings. The method has proved reliable in internal tests.

ImmunoIntel: Diagnostic method for ranking immunotherapy treatments for cancer in order of effectiveness for any individual patient. Agreements are now available, subject to funding, to provide screening of patients for large scale trials with big pharma.